Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension

Journal of Cardiovascular Pharmacology
H ShionoiriY Kaneko

Abstract

The acute effects and pharmacokinetic properties of an angiotensin converting enzyme (ACE) inhibitor, ramipril, and its potent active diacid metabolite, ramiprilate, were investigated. Hypertensive patients with impaired renal function (IRF; n = 6) and with normal renal function (NRF; n = 5) were studied. The terminal half-life of ramiprilate in IRF was longer than that in NRF. The peak plasma concentrations of ramipril and ramiprilate in IRF were higher than those in NRF. The area under the plasma level-time curves of ramipril and ramiprilate in IRF were greater than those in NRF. A significant inverse correlation was found between creatinine clearance and area under the plasma level-time curve.

Citations

Jan 1, 1993·European Journal of Clinical Pharmacology·T W GehrK L Duchin
Jan 10, 2006·BMC Clinical Pharmacology·David G Levitt, Rik C Schoemaker
Aug 22, 2006·Journal of Clinical Pharmacology·Jaclyn M LeBlancJerome J Schentag

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

European Journal of Clinical Pharmacology
H SchunkertH G Sieberth
Drug Metabolism and Disposition : the Biological Fate of Chemicals
Lichuan Liu, K S Pang
© 2022 Meta ULC. All rights reserved